LDL-apheresis in the treatment familial hypercholesterolemia

Czech version

Authors: Vladimír Bláha ¹; Milan Bláha ²; Miriam Lánská ²; Eduard Havel ¹; Pavel Vyroubal ¹; Zdeněk Zadák ¹; Pavel Žák ²; Luboš Sobotka ¹
Authors‘ workplace: III. interní gerontometabolická klinika LF UK a FN Hradec Králové, přednosta prof. MUDr. Luboš Sobotka, CSc. ¹; IV. interní hematologická klinika LF UK a FN Hradec Králové, přednosta doc. MUDr. Pavel Žák, Ph. D. ²
Published in: Vnitř Lék 2014; 60(11): 970-976
Category: Reviews

Overview

LDL-apheresis is an extracorporeal elimination technique, which specifically removes LDL-cholesterol from the circulation. There are six methods for the selective LDL-cholesterol removal these days. The main indications for LDL-apheresis are the diagnosis of homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia which is refractory the standard care and intolerance of routine care, and also patients with lipoprotein(a) increase resistant to the farmacotherapy. There is still debate which LDL-cholesterolemia is indication for LDL-apheresis therapy, and the recommendation differs among various countries. Despite large randomized trials are missing, there are several good quality studies to conclude, that the beneficial cardiovascular effects of LDL-apheresis in severe hypercholesterolemia are important and beneficial

Key words:
atherosclerosis – cardiovascular disease – hypercholesterolemia – hypolipidemic therapy – LDL-apheresis

Sources

1. Al-Shaikh AM, Abdullah MH, Barclay A et al. Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial hypercholesterolemia. Cardiol Young 2002; 12(2): 105–112.

2. Beigel R, Beigel Y. Homozygous familial hypercholesterolemia: long term clinical course and plasma exchange therapy for two individual patients and review of the literature. J Clin Apher 2009; 24(6): 219–224.

3. Benlian P. Genes of lipoprotein metabolism. In: Genetics of dyslipidemia. Kluwer Academic Publishers: London 2001. ISBN 0–7923–7362–6. 41–181.

4. Bláha M, Lánská M, Bláha V. Pregnancy in homozygous familial hypercholesterolemia – importance of LDL-apheresis. Atherosclerosis Suppl. Přijato do tisku 2014.

5. Bláha M, Rencová E, Malý R et al. Léčba hemorheoferézou (současný stav a vlastní zkušenosti). Aktuality z nefrologie 2008; 14(3): 118–124.

6. Bláha M, Zadák Z, Havel E et al. Léčba těžké hyperlipoproteinémie LDL-aferézou. Transfuze dnes 1997; 19: 9–10.

7. Borberg H. The lower the better: target values after LDL-Apheresis and semi-selective LDL-elimination therapies. Transfus Apher Sci 2013; 48(2): 203–206.

8. Borberg H. 26 years of LDL-apheresis: a review of experience. Transfus Apher Sci 2009; 41(1): 49–59.

9. Cuchel M, Bruckert E, Ginsberg HN et al. European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35(32): 2146–2157.

10. Dann EJ, Shamir R, Mashiach T et al. Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis. Transfus Apher Sci 2013; 49(2): 268–277.

11. Fernández-Fuertes LF, Tapia Martín M, Nieves Plá I et al. Low-density lipoprotein apheresis using double filtration plasmapheresis: 27-month use in a child with homozygous familial hypercholesterolemia. Ther Apher Dial 2010; 14(5): 484–485.

12. Fischer S, Schatz U, Julius U. Current standards in diagnosis and therapy of hyperlipoproteinemia. Atheroscler Suppl 2013; 14(1): 15–18.

13. Græsdal A, Bogsrud MP, Holven KB et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol 2012; 6(4): 331–339.

14. Harada-Shiba M, Arai H, Oikawa S et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb 2012; 19(12): 1043–1060.

15. Hudgins LC, Kleinman B, Scheuer A et al. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 2008; 102(9): 1199–1204.

16. Julius U, Taseva K, Fischer S et al. Current situation of lipoprotein apheresis in Saxony. Atheroscler Suppl 2013; 14(1): 51–55.

17. Kalinová M, Zadák Z, Bláha M. Léčba hyperlipoproteinémií kontinuálními plazmaferézami. Lék Zprávy (Hradec Králové) 1981; 26: 135–142.

18. Kardaş F, Cetin A, Solmaz M et al. Successful treatment of homozygous familial hypercholesterolemia using cascade filtration plasmapheresis. Turk J Haematol 2012; 29(4): 334–341.

19. Keller C. LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience. Atheroscler Suppl 2009; 10(5): 21–26.

20. Klingel R, Fassbender C, Fassbender T et al. Rheopheresis: rheologic, functional, and structural aspects. Ther Apher 2000; 4(5): 348–357.

21. Lánská M, Bláha M, Žák P. Extrakorporální eliminace cholesterolu u familiární hypercholesterolémie – srovnání dvou metodik. Transfuze a hematologie dnes. Přijato do tisku 2014.

22. Leebman J, Roeseler E, Julius U et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013; 128(24): 2567–2576.

23. Mabuchi H, Koizumi J, Shimizu M et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998; 82(12): 1489–1495.

24. Makino H, Harada-Shiba M. Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther Apher Dial 2003; 7(4): 397–401.

25. Marais AD, Blom DJ. Recent advances in the treatment of homozygous familial hypercholesterolaemia. Curr Opin Lipidol 2013; 24(4): 288–294.

26. McGowan MP. Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol – the role of LDL-apheresis. J Clin Lipidol 2013; 7(3 Suppl): S21-S26.

27. Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34(45): 3478–3490.

28. Page MM, Bell DA, Hooper AJ et al. Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Pract Res Clin Endocrinol Metab 2014; 28(3): 387–403.

29. Palcoux JB, Atassi-Dumont M, Lefevre P et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial 2008; 12(3): 195–201.

30. Pták J. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis. Transfus Apher Sci 2004; 30(2): 125–129.

31. Schwarz J, Winters JL, Padmanabhan A et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013; 28(3): 145–284.

32. Stefanutti C. Treatment of severe genetic dyslipidemia: where are we going? Ther Apher Dial 2013; 17(2): 122–123.

33. Stefanutti C, Vivenzio A, Di Giacomo S et al. Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis. Transfusion 2009; 49(7): 1461–1470.

34. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 1981; 2(8254): 1005–1007.

35. Thompson GR, Barbir M, Davies D et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010; 208(2): 317–321.

36. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Br Med J (Clin Res Ed) 1985; 291(6510): 1671–1673.

37. Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler Suppl 2013; 14(1): 67–70.

38. Watts GF, Gidding S, Wierzbicki AS et al. Integrated guidance on the care of familial hypercholesterolemia from International FH Foundation. J Clin Lipidol 2014; 8(2): 148–172.

39. Winters JL. American society for apheresis guidelines on the use of apheresis in clinical practice: Practical, concise, evidence-based recommendations for the apheresis practitioner. J Clin Apher 2014; 29(4): 191–193.

40. Winters JL. Low-density lipoprotein apheresis: principles and indications. Semin Dial 2012; 25(2): 145–151.